• Shanghai Bio-heart’s non-wholly owned subsidiary AngioCare appointed Giorgio Gobbi as vice president, global therapy development.
• Gobbi will lead global therapy development for AngioCare’s Iberis renal denervation system, including KOL engagement, post-market studies, training standards.
• Appointment supports AngioCare’s overseas push with Biosensors International to commercialize Iberis in multiple markets.
• Planned expansion targets Europe, Asia-Pacific, Middle East, Latin America alongside clinical evidence generation and regulatory filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bio-heart Biological Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260907-12324001), on September 07, 2026, and is solely responsible for the information contained therein.